Cepheid (CPHD) Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia
More News related to CPHD
- Cepheid to Webcast Upcoming Financial Presentations
- Cepheid (CPHD) Tops Q3 EPS Views; Guides
- Cepheid Reports 2009 Third Quarter Results
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- Unusual 11 Mid-Day Movers 10/14: CHIO, ACPW, JADE, CNO Higher; CXM, HILL, UCBH, UPI Lower
More News related to Corporate News
- Trading Radar for 12/3: Marvell (MRVL), Toll Bros. (TOL), Del Monte (DLM), Smith & Wesson (SWHC) Report
- Unusual 11 Mid-Day Movers 12/02: ABCW, BIOF, GRH, STEM Higher; HEB, HDY, BGP, CBAK Lower
- Notable ETF Movers 12/2: GDX, TUR Up; UNG, USO, THD Down
- Notable Analyst Rating Changes 12/2: AMR/UAUA, RFMD, STI, SAY, KBH, BBT Upgraded; STZ, MTL, BWP, POM Downgraded
- Notable Mergers and Acquisitions of the Day 12/2: DDRX/GMCR/PEET, AGU/CF, ZINC
Cepheid (Nasdaq: CPHD) announced the release of its improved Xpert(R) BCR-ABL Monitor test to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. With improved time-to-results, the test now detects the BCR-ABL chromosomal translocation in about 2 hours as compared to 2.5 hours for the original product release. The test is intended to aid European clinicians in the monitoring of patients with Chronic Myelogenous Leukemia (CML). The test runs on Cepheid's GeneXpert(R) System, the world's leading on-demand molecular diagnostic platform.
Stay up to date on your stocks at EasyStockAlerts.com
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.55Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
